AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17229548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with single pre‐surgical dose of two tablets amoxicillin/clavulanate 1000/62.5 mg
Number of subjects: 225
Study 17229548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive post‐surgery therapy with two tablets amoxicillin/clavulanate 1000/62.5 mg BID for 5 days
Number of subjects: 225
Study 17229548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 17229548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prophylactic and therapeutic regimens
Number of subjects: 225
Study 15172898 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (n = 22)
Number of subjects: 45
Study 15172898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 45
Study 11641547 — intervention group
Group type: EXPERIMENTAL
Intervention: SensiCath Blood Gas Monitoring System
Number of subjects: 44
Study 11641547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 9757201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of granisetron
Number of subjects: 38
Study 9757201 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip infusion of granisetron over 30 minutes
Number of subjects: 38
Study 7532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 4 weeks
Number of subjects: 119
Study 7532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 2 weeks
Number of subjects: 119
Study 7532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg every 4 weeks
Number of subjects: 119
Study 7532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg every 2 weeks
Number of subjects: 119
Study 7532991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (various regimens) in prostate cancer patients
Number of subjects: 119
Study 3171001 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 8
Study 3171001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 Gy in 37 fractions (conventional fractionation)
Number of subjects: 3216
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy in 20 fractions (hypofractionation)
Number of subjects: 3216
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 Gy in 19 fractions (hypofractionation)
Number of subjects: 3216
Study 29722660 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (74 Gy)
Number of subjects: 3216
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (60 Gy)
Number of subjects: 3216
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionation (57 Gy)
Number of subjects: 3216
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Number of subjects: 3216
Study 29722660 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 Gy schedule
Number of subjects: 3216
Study 28239017 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted evidence-based risk reduction program
Number of subjects: 251
Study 28239017 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 251
Study 25425214 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 91
Study 25425214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 22961714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, folinic acid and oxaliplatin
Number of subjects: 34
Study 22961714 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of floxuridine with systemic irinotecan
Number of subjects: 34
Study 22961714 — intervention group
Group type: EXPERIMENTAL
Intervention: (1) H MRS
Number of subjects: 34
Study 20956486 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (four cycles of 60 s reperfusion and 60 s of reocclusion before permanent reperfusion)
Number of subjects: 76
Study 20956486 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous coronary intervention
Number of subjects: 76
Study 18570226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam (LZP)
Number of subjects: 23
Study 16914475 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece acrylic IOL
Number of subjects: 100
Study 16914475 — intervention group
Group type: COMPARATOR
Intervention: Three-piece acrylic IOL
Number of subjects: 100
Study 16914475 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece acrylic IOL (combined vitrectomy)
Number of subjects: 100
Study 14672266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30
Study 14672266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8996762 — intervention group
Group type: EXPERIMENTAL
Intervention: Indefinite, high dose HBIG (10,000 mu or 40,000 mu/dose depending on HBV DNA status pretransplant)
Number of subjects: 17
Study 8996762 — intervention group
Group type: EXPERIMENTAL
Intervention: Indefinite, high dose HBIG
Number of subjects: 17
Study 8996762 — intervention group
Group type: COMPARATOR
Intervention: No immunoprophylaxis
Number of subjects: 17
Study 8877207 — intervention group
Group type: EXPERIMENTAL
Intervention: Serous fluid
Number of subjects: 222
Study 8877207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoid fluid
Number of subjects: 222
Study 8877207 — intervention group
Group type: COMPARATOR
Intervention: Both serous and mucoid groups
Number of subjects: 222
Study 3532697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg i.v. + 50 mg orally q.i.d.)
Number of subjects: 212
Study 3532697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 3532697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 212
Study 30486374 — intervention group
Group type: EXPERIMENTAL
Intervention: CPLE dentifrice
Number of subjects: 100
Study 30486374 — intervention group
Group type: EXPERIMENTAL
Intervention: CPLE dentifrice and mouthwash
Number of subjects: 100
Study 30486374 — intervention group
Group type: COMPARATOR
Intervention: SLS-free enzyme-containing dentifrice
Number of subjects: 100
Study 30486374 — intervention group
Group type: COMPARATOR
Intervention: SLS-free enzyme-containing dentifrice with essential oil mouthwash
Number of subjects: 100
Study 27659881 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography (CAG) and percutaneous coronary intervention (PCI) within 2 hours
Number of subjects: 552
Study 27659881 — intervention group
Group type: COMPARATOR
Intervention: Initial deferral with CAG and PCI after neurological recovery
Number of subjects: 552
Study 25420455 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP + Fe (2.5 mg iron as NaFeEDTA)
Number of subjects: 287
Study 25420455 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP + Fe
Number of subjects: 287
Study 25420455 — intervention group
Group type: COMPARATOR
Intervention: MNP - Fe
Number of subjects: 287
Study 25420455 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP + Fe and MNP - Fe
Number of subjects: 287
Study 23220254 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (reading an educational guide and participating in an educational session)
Number of subjects: 0
Study 23220254 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 22352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol XL 50 mg + Amlodipine 5 mg
Number of subjects: 402
Study 22352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol XL 25 mg + Amlodipine 2.5 mg
Number of subjects: 402
Study 22352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol XL 50 mg
Number of subjects: 402
Study 22352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol XL 25 mg
Number of subjects: 402
Study 22352120 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 402
Study 18061407 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a deprived urban environment
Number of subjects: 30
Study 18061407 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness relaxation task
Number of subjects: 30
Study 16761467 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 0
Study 16761467 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study 14700349 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 143
Study 14700349 — intervention group
Group type: EXPERIMENTAL
Intervention: DFA test
Number of subjects: 143
Study 14700349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Culture and DFA
Number of subjects: 143
Study 11105975 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconstrained standing with mechanical loading, visual conditions, type of support surface, and sole of the shoes
Number of subjects: 0
Study 11105975 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of centre of pressure data
Number of subjects: 0
Study 9370141 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (45 mg beta-carotene, 825 mg alpha-tocopherol, and 450 mg ascorbic acid daily for three weeks)
Number of subjects: 26
Study 9370141 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant supplementation (BMT(-) group)
Number of subjects: 26
Study 9370141 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (N = 10) supplemented with the same doses as BMT(+)
Number of subjects: 26
Study 1316400 — intervention group
Group type: COMPARATOR
Intervention: Candoxatril (single oral dose)
Number of subjects: 50
Study 1316400 — intervention group
Group type: COMPARATOR
Intervention: High-sodium diet
Number of subjects: 50
Study 1316400 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 50
Study 1316400 — intervention group
Group type: COMPARATOR
Intervention: Crossover study design
Number of subjects: 50
Study 3982016 — intervention group
Group type: EXPERIMENTAL
Intervention: FSCP-D (Femoral Systolic Pressures measured by compression technique using disappearance of the profunda femoris Doppler signal)
Number of subjects: 0
Study 3982016 — intervention group
Group type: EXPERIMENTAL
Intervention: FSCP-P (Femoral Systolic Pressures measured by compression technique using flattening of thigh plethysmographic waveforms)
Number of subjects: 0
Study 3982016 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSP (Proximal Thigh Systolic Pressures)
Number of subjects: 0
Study 3982016 — intervention group
Group type: EXPERIMENTAL
Intervention: FSCP-D (using soft bladder for arterial compression)
Number of subjects: 0
Study 30020512 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week yoga-based lifestyle intervention (YBLI)
Number of subjects: 260
Study 30020512 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention (DI)
Number of subjects: 260
Study 29397291 — intervention group
Group type: COMPARATOR
Intervention: Cervical plexus block alone (Group 1)
Number of subjects: 0
Study 29397291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical plexus block + Mandibular block (Group 2)
Number of subjects: 0
Study 26628419 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 341
Study 24658390 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 151
Study 24658390 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study 23111108 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet‐administered cognitive behavior therapy (iCBT) for 9 weeks
Number of subjects: 96
Study 23111108 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 96
Study 20602280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral gel
Number of subjects: 60
Study 20602280 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study 18008240 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose sulfadoxine-pyrimethamine (SP)
Number of subjects: 387
Study 18008240 — intervention group
Group type: COMPARATOR
Intervention: 2-dose sulfadoxine-pyrimethamine (SP)
Number of subjects: 387
Study 18008240 — intervention group
Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine (SP) IPT
Number of subjects: 387
Study 15677374 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron-folic acid (1 tablet/dose, 20 mg elemental iron and 0.1 mg folic acid/tablet)
Number of subjects: 803
Study 15677374 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly iron-folic acid (2 tablets/dose, 20 mg elemental iron and 0.1 mg folic acid/tablet)
Number of subjects: 803
Study 11981066 — intervention group
Group type: EXPERIMENTAL
Intervention: cerivastatin 0.15 mg/day
Number of subjects: 40
Study 11981066 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 10349966 — intervention group
Group type: COMPARATOR
Intervention: Occipital gamma and frontal beta induced activities during variable delay durations
Number of subjects: 0
Study 10349966 — intervention group
Group type: COMPARATOR
Intervention: Control condition (fixed short delay)
Number of subjects: 0
Study 7594155 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 84
Study 7594155 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 84
Study 1428381 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual acupuncture
Number of subjects: 36
Study 1428381 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 36
Study 1428381 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 36
Study 6701692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative intracavitary caesium‐137 followed by a Wertheim hysterectomy (group 1)
Number of subjects: 92
Study 6701692 — intervention group
Group type: COMPARATOR
Intervention: Staging laparotomy with biopsy of suspicious lymph nodes (group 2)
Number of subjects: 92
Study 6701692 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation for patients with tumour invasion of the parametrium
Number of subjects: 92
Study 6701692 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation for patients with tumour invasion of pelvic lymph nodes
Number of subjects: 92
Study 31208463 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization restrictions
Number of subjects: 0
Study 31208463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization power distribution examination
Number of subjects: 0
Study 28786530 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin (20 mg) added to canagliflozin (C + T group)
Number of subjects: 0
Study 28786530 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to canagliflozin (C + P group)
Number of subjects: 0
Study 27165661 — intervention group
Group type: EXPERIMENTAL
Intervention: Khat (juice mixed with 45 g of ground khat leaves)
Number of subjects: 21
Study 27165661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (33 ml of fruit juice)
Number of subjects: 21
Study 23595769 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction (Group DB)
Number of subjects: 108
Study 23595769 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction (Group SB)
Number of subjects: 108
Study 23595769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (DB and SB)
Number of subjects: 108
Study 23036877 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical exercise therapy (MET)
Number of subjects: 17
Study 23036877 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic surgery
Number of subjects: 17
Study 20375180 — intervention group
Group type: EXPERIMENTAL
Intervention: CJ-13,610 (30 mg single oral dose)
Number of subjects: 0
Study 20375180 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (as an inhibitor)
Number of subjects: 0
Study 20375180 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-species allometric scaling from dog pharmacokinetic studies
Number of subjects: 0
Study 20375180 — intervention group
Group type: COMPARATOR
Intervention: Single-species allometric scaling from rat pharmacokinetic studies
Number of subjects: 0
Study 17822770 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg twice daily
Number of subjects: 25
Study 17822770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16286177 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control antiarrhythmic drugs
Number of subjects: 245
Study 16286177 — intervention group
Group type: COMPARATOR
Intervention: Rate-controlling drugs
Number of subjects: 245
Study 12358651 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed re-expansion inspiratory manoeuvre (TRIM) for 3 min
Number of subjects: 20
Study 12358651 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen for 3 min
Number of subjects: 20
Study 10397563 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T plus 3TC (300 mg/day)
Number of subjects: 299
Study 10397563 — intervention group
Group type: EXPERIMENTAL
Intervention: ddl plus 3TC (300 mg/day)
Number of subjects: 299
Study 7547093 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg day‐1
Number of subjects: 12
Study 7547093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1963170 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP (10 mg in an intravenous bolus)
Number of subjects: 27
Study 1963170 — intervention group
Group type: COMPARATOR
Intervention: MCP with bromocriptine (5 mg p.o. 3 h before MCP)
Number of subjects: 27
Study 1963170 — intervention group
Group type: COMPARATOR
Intervention: MCP with atropine (1.2 mg in an intravenous bolus just before MCP)
Number of subjects: 27
Study 1963170 — intervention group
Group type: COMPARATOR
Intervention: MCP with pirenzepine (40 mg in an intravenous bolus 10 min before MCP)
Number of subjects: 27
Study 1963170 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP with metergoline (10 mg/day p.o. in 5 divided doses for 4 days before MCP)
Number of subjects: 27
Study 1963170 — intervention group
Group type: COMPARATOR
Intervention: MCP with ketanserin (10 mg as a slow 3-min intravenous injection, 5 min before MCP)
Number of subjects: 27
Study 7074794 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (480 mg/day)
Number of subjects: 16
Study 7074794 — intervention group
Group type: COMPARATOR
Intervention: propranolol (160-320 mg/day)
Number of subjects: 16
Study 30855472 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-rate feedback infusion plus demand dosing
Number of subjects: 78
Study 30855472 — intervention group
Group type: COMPARATOR
Intervention: Constant-rate background infusion plus demand dosing
Number of subjects: 78
Study 30229712 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 140 ml
Number of subjects: 12
Study 30229712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 27417659 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits focused on infant feeding
Number of subjects: 1043
Study 25165486 — intervention group
Group type: EXPERIMENTAL
Intervention: Path-counting formulas for generalized kinship coefficients
Number of subjects: 0
Study 25165486 — intervention group
Group type: COMPARATOR
Intervention: Recursive method for computing condensed identity coefficients
Number of subjects: 0
Study 21892677 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 7808
Study 21892677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 19022653 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (Patient-Controlled Epidural Analgesia)
Number of subjects: 66
Study 19022653 — intervention group
Group type: COMPARATOR
Intervention: PCEA + CBI (Continuous Background Infusion)
Number of subjects: 66
Study 19022653 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 66
Study 19022653 — intervention group
Group type: COMPARATOR
Intervention: PCEA + CBI
Number of subjects: 66
Study 17228021 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP plus involved-field radiotherapy
Number of subjects: 576
Study 17228021 — intervention group
Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 576
Study 15277962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumotachograph (PCFp)
Number of subjects: 62
Study 15277962 — intervention group
Group type: COMPARATOR
Intervention: Portable peak flow meter (PCFm)
Number of subjects: 62
Study 11939614 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine containing alcohol (0.8 g/kg)
Number of subjects: 324
Study 11939614 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive alcohol consumption (>21 units/week)
Number of subjects: 324
Study 11939614 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized wine
Number of subjects: 324
Study 9637639 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (2.5 microg/ml, 10 ng x kg(‐1) x min(‐1))
Number of subjects: 54
Study 9637639 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine infusion (5 mg/ml, 50 microg x kg(‐1) x min(‐1))
Number of subjects: 54
Study 7726544 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk served at lunch for 3 months (Intervention group)
Number of subjects: 147
Study 7726544 — intervention group
Group type: COMPARATOR
Intervention: Water served at lunch (Control group)
Number of subjects: 147
Study 2574194 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (N = 11)
Number of subjects: 16
Study 2574194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 5)
Number of subjects: 16
Study 31424235 — intervention group
Group type: EXPERIMENTAL
Intervention: Romance narrative
Number of subjects: 405
Study 31424235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual narrative
Number of subjects: 405
Study 31424235 — intervention group
Group type: COMPARATOR
Intervention: Control narrative
Number of subjects: 405
Study 30338365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-source dual-energy CT (SS-DECT)
Number of subjects: 102
Study 30338365 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation dual-source dual-energy CT (DS-DECT)
Number of subjects: 102